



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/976,560	11/24/1997	NELSON B. FREIMER	UCAL-250-02U	2046

7590 08/08/2003

PAULA A. BORDEN
BOZICEVIC, FIELD & FRANCIS, LLP
200 MIDDLEFIELD ROAD
SUITE 200
MENLO PARK, CA 94025

EXAMINER

MYERS, CARLA J

ART UNIT

PAPER NUMBER

1634

DATE MAILED: 08/08/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	08/976,560	FREIMER ET AL.	
	Examiner Carla Myers	Art Unit 1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 21 May 2003.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-7, 9-12 and 25-29 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) 28 and 29 is/are allowed.

6) Claim(s) 1-7, 9-12 and 25-27 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No. _____.

3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____

4) Interview Summary (PTO-413) Paper No(s). _____

5) Notice of Informal Patent Application (PTO-152)

6) Other: _____

1. This action is in response to the amendment filed May 21, 2003. Claims 1-7, 9-12 and 25-29 are pending. Applicant's arguments have been fully considered but are not persuasive to overcome all grounds of rejection. All rejections not reiterated herein are hereby withdrawn. This action is made final.

Claim Rejections - 35 USC § 112

2. Claims 9-12 and 27 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for (i) methods of detecting an increased susceptibility to bipolar mood disorder (BP) wherein said methods comprise performing a pedigree analysis for the individual's family and analyzing the DNA from family members for linkage of markers on the short arm of chromosome 18 between and inclusive of SAVA5 and ga203, D18S1140 and ga203, SAVA5 and W3422, S18S1140 and W3422, D18S1140 and ta201 and S18S59 and ta201, and (ii) methods of detecting an increased susceptibility to bipolar mood disorder by assaying for the presence of a 154 bp allele at D18S59 or a 271 bp allele at D18S476 wherein the presence of either of said alleles is indicative of an increased susceptibility to BP, does not reasonably provide enablement for (a) a method of detecting an increased susceptibility to bipolar mood disorder in the general population by detecting any polymorphism between SAVA5 and ga203 wherein any polymorphism associated with BP indicates an increased susceptibility to develop BP or (b) a method for detecting the presence of any BP susceptibility DNA polymorphism wherein said method comprises detecting a polymorphism over-represented on disease chromosomes or typing blood relatives to detect the presence of a new polymorphism. The specification does not

enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

The following factors have been considered in formulating this rejection (*In re Wands*, 858F.2d 731, 8 USPQ2d 1400 (Fed. Cir. 1988): the breadth of the claims, the nature of the invention, the state of the prior art, the relative skill of those in the art, the predictability or unpredictability of the art, the amount of direction or guidance presented, the presence or absence of working examples of the invention and the quantity of experimentation necessary.

The claims as broadly written include methods of detecting an increased susceptibility to bipolar mood disorder by detecting any DNA polymorphisms within a 300 kb or 500 kb region of chromosome 18 between and inclusive of the markers SAVA5 and ga203. In view of the teachings in the specification, it has been interpreted that the claims as broadly written include methods in which any type of genetic alteration is detected in the region of SAVA5 to ga203 as indicative of susceptibility to BP (see, for example, pages 12-13 of the specification). Accordingly, the claims include methods in which any substitution, addition, deletion, translocation or splice variant of a particular gene is detected as indicative of BP. The claims also include methods which identify novel polymorphisms that are associated with BP. However, the specification has not taught a representative number of polymorphisms within the SAVA5 to ga203 region that can be used to diagnose bipolar mood disorder within the general population. The claims as written are not commensurate in scope with the disclosure for the following reasons:

The specification teaches that markers within chromosome 18 were used to delineate a 500 kb and 300 kb subregion of chromosome 18p that is associated with bipolar mood disorder. Haplotype analysis was performed by assaying blood samples from affected and unaffected family members. Through this analysis, a region from SAVA5 to ga203 of chromosome 18 was identified as being linked with bipolar susceptibility disorder. Accordingly, the specification teaches methods in which susceptibility to bipolar mood disorder can be determined by performing a pedigree analysis wherein said analysis detects the presence of a polymorphic marker between SAVA5 and ga203 of chromosome 18 in a test individual, wherein said polymorphic marker is known to be present in affected family members and is absent in unaffected family members. Furthermore, the specification teaches that a 154 bp allele of D18S59 and a 271 bp allele of D18S476 are each over-represented in individuals having BP, as compared to individuals in the general population. However, the claims as written include methods in which any polymorphism between SAVA5 to ga203 is detected in the general population as indicative of an increased susceptibility to BP. The teachings in the specification of 2 polymorphic markers (i.e., the 154 bp allele of D18S59 and the 271 bp allele of D18S476) is not representative of the claimed genus of any DNA polymorphism between SAVA5 to ga203 associated with BP. While the stated D18S59 and D18S476 markers can be used to analyze the general population for increased susceptibility to BP, the ability to use other, unidentified polymorphisms to diagnose BP is highly unpredictable. Additionally, the specification does not identify any particular single nucleotide polymorphisms that are associated with BP and does not teach any

other type of genetic alterations that are associated with BP. As discussed in the specification, extensive experimentation is required to identify additional polymorphisms and other types of genetic alterations that are associated with BP. The specification (beginning at page 31) provides an outline of the research that can be performed to identify polymorphisms associated with BP. In particular, the specification teaches that a P1 clonal library can be made to identify candidate cDNAs which would then be sequenced and compared to nucleic acid databases to identify a gene or genes which may constitute the bipolar susceptibility gene. The cDNAs identified that map to the minimal candidate region are then used as probes to screen the P1 phage contig library. This screening then identifies new microsatellite markers which are used to genotype the linkage disequilibrium sample. The cDNAs identified by these screens are then used to screen patient DNA for mutations and polymorphisms associated with bipolar disorders.

The art corroborates the unpredictability in identifying polymorphisms and mutations associated with BP and in identifying a specific loci within chromosome 18 that is definitively associated with BP. For example, McInnes teach that interpreting results from linkage analysis of bipolar mood disorder and other behavioral phenotypes is very difficult and often misleading because behavioral phenotypes are difficult to define, as they are etiologically heterogeneous and there is a lack of knowledge as to the mode of transmission of these diseases. McInnes concluded that it is unlikely that any one linkage study will yield sufficient evidence to localize a gene for any psychiatric disorder (page 13060, col. 2, paragraph 1). However, McInnes performed a genome

screening analysis for possible genes associated with BP and found suggestive lod scores in segments 18q, 18p and 11p, including an marker D18S59 (see abstract and Table 1). McInnes state that the point of their study was to detect chromosomal regions which merit further investigation (page 13063, col. 1, paragraph 1) and McInnes specifically identified the telomere of 18p as a region that should be further studied (page 13064, col. 1). McInnes teaches that genome screening is the first step of a multi-step process for identifying genes for complex traits and that several additional steps and experiments would be required to delineate a clear candidate region (page 13064, col. 2). Easterling (1997) discloses a high resolution integrated map of 18p11.2, which is a 40 cM region believed to contain a potential bipolar susceptibility locus (see Figure 1). However, even with these high resolution maps and linkage studies, no specific polymorphisms or individual loci were identified as the bipolar susceptibility locus as of 1999. Gerson (1998) reviewed the progress in identifying genes associated with manic-depressive illness and concluded that while chromosome 18, and particularly the short arm of chromosome 18, is one of the best candidate locations for a bipolar susceptibility gene, and that the positive linkage results represent important progress, scientists are still a long way from demonstrating a disease mutation correlated with bipolar illness (page 239, col. 2). Nothen (1999) concluded that as late as 1999 that the data in the art supports the hypothesis that a susceptibility locus exists and may specifically exist on chromosome 18, but does not provide a reasonable expectation that polymorphisms in the region of 18p are associated with a bipolar susceptibility locus or what that locus will be.

The teachings in the specification do not provide a reasonable expectation that one of skill in the art can identify polymorphisms associated with bipolar mood disorder or can identify a bipolar susceptibility locus without undue experimentation because of the high level of unpredictability in the art (as discussed above) and because the specification has not provided evidence that would allow the skilled artisan to predict the location and identity of additional bipolar susceptibility polymorphisms. The specification presents data defining a smaller region of the 18pter which has a higher probability of containing a susceptibility locus, but as of 1999, the art indicates that scientists are a long way from pinpointing specific polymorphisms and mutations that are associated with bipolar disease. The specification describes a research project for searching for polymorphisms that may exist in the defined region but the protocol described constitutes undue experimentation because the skilled artisan would be required to perform a large amount of essentially random screening of the defined region and would not be able to reasonably predict from the specification the identity of the polymorphisms associated with BP. Furthermore, the claims as written are claims to a research project without a predictable outcome because they encompass methods which detect novel bipolar disease susceptibility polymorphisms. The art makes clear that this objective is of great interest and the target of extensive research by many groups. In fact, many groups have taken the same approach as described in the specification for identifying such a bipolar locus without success. The specification essentially suggests that the artisan should analyze all possible polymorphisms within the 500 kb region of SAVA5 to ga203 and then determine which polymorphisms within

this region “work” (i.e., determine which polymorphisms within the broad genus of polymorphisms could be used to diagnose BP).

The fact that the specification presents evidence of linkage to the recited markers in a defined region of chromosome 18 is useful in analyzing family members by pedigree analysis for the inheritance of markers within this defined region. However, this finding does not allow one of skill in the art to screen the general population for any polymorphism between SAVA5 and ga203 for susceptibility to BP. The region between SAVA5 and ga203 is expected to contain numerous polymorphisms and mutations that are not associated with BP. Thereby, the detection of these variants in the general population would not be predictive of susceptibility to BP. Only specific polymorphisms and mutations within the defined region will be found to be correlated with BP. The specification does not provide sufficient guidance as to how to apply the claimed method of diagnosis to the general population by detecting the presence of any polymorphism between SAVA5 and ga203. As stated in *Vaek* (20 USPQ2d 1438), the “specification must teach those of skill in the art how to make and how to use the invention as *broadly* as it is claimed” (emphasis added). The amount of guidance needed to enable the invention is related to the amount of knowledge in the state of the art as well as the predictability in the art. *In re Fisher* 427 F. 2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). Predictability or lack thereof in the art refers to the ability of one of skill in the art to extrapolate the disclosed or known results to the invention that is claimed. If one of skill in the art can readily anticipate the effect of a change in the subject matter to which the claimed invention is directed, then there is predictability in

the art. On the other hand, if one skilled in the art cannot readily anticipate the effect of a change in the subject matter to which the claimed invention is directed, then there is unpredictability in the art." With respect to the present invention, one cannot readily anticipate what additional polymorphisms may exist between SAVA5 and ga203 which are associated with BP and which could be used to screen any individual for susceptibility to BP. In view of the high level of unpredictability in the art and the lack of guidance provided in the specification, undue experimentation would be required for one of skill in the art to practice the invention as it is broadly claimed.

RESPONSE TO ARGUMENTS:

In the response filed May 21, 2003, Applicants argue that they have described a number of polymorphisms associated with BP and have provided guidance as to how to identify additional polymorphisms. Applicants argue that the interval between SAVA5 and ga203 is narrow and that they have exemplified a number of polymorphisms within this region. Applicants also assert that they have taught the methodology for detecting polymorphisms and that given the guidance provided in the specification one could readily identify additional polymorphisms. It is stated that the specification provides working examples of polymorphisms associated with BP, how they are detected and how their association is determined. Applicants thereby conclude that such teachings provide a reasonable correlation to the entire scope of the claimed invention. It is further argued that the declaration of Alison McInnes provides evidence that those of skill in the art could identify additional polymorphisms without undue experimentation.

Applicants maintain that the experimentation to identify additional polymorphisms is merely routine.

Applicants arguments have been fully considered but are not persuasive because it is maintained that a representative number of polymorphisms have not in fact been identified and that the identification of a representative number of additional polymorphism in the stated 500kb interval remains unpredictable.

Firstly, it is pointed out that the present specification teaches only 2 polymorphisms that are associated with BP. In particular, the specification has established only that allele 154 at D18S59 and allele 271 at D18S476 are over-represented in populations having BP. However, the claims are inclusive of any polymorphism within a 500 kb interval. No additional polymorphisms are defined in the specification in terms of their structure or specific location. Thus, the teaching in the specification of these 2 alleles is not considered to be representative of the broadly claimed genus of any polymorphism on chromosome 18p between SAVA5 and ga203 associated with BP.

Secondly, with respect to the declaration of Alison McInnes, it is maintained that this declaration does not establish that the identification of additional polymorphisms associated with BP can be performed without undue experimentation. The fact that the declaration teaches that additional polymorphisms were identified using Applicant's methodology does not establish that the identification process was routine and did not require undue experimentation. While the general techniques used to screen for genetic alterations were known and readily used in the art, the identification of specific

polymorphisms associated with BP is not predictable. The references cited by Applicants, namely Escamilla (1999 and 2001) provide further evidence of the association between BP and markers within the SAVA5 and ga203 interval. As discussed previously, the Escamilla (2001, pages 212-213) reference, in which the present inventors are listed as co-authors states:

“The failure to detect association with AHR in the phase I genotyping study likely reflects low power from the very small sample suitable for AHR testing, as well as the wide spacing of the markers. These comparisons require an important caveat, namely that none of the association results reported here meet unequivocal thresholds for statistical significance; therefore it is not possible to state, based on this data, how the tests perform in locating a definitive gene predisposition locus for BP-I. Further evaluation of these chromosomal regions with larger samples and additional markers will be required to definitely prove whether BP-I predisposition genes are located at these sites on chromosome 18 and to gain a more clear assessment of the power of the AHR and LD-T approaches for gene mapping of complex traits in population isolates.”

Applicants argue that the teachings in the declaration that 5 out of 34 polymorphisms analyzed were found to be associated with BP is a strong indication that the instant specification is enabling and that the methods disclosed in the specification can be carried out without undue experimentation. However, while the declaration establishes that additional polymorphisms were identified that are associated with BP, the declaration does not establish that such polymorphisms were identified without undue experimentation. The fact that the methodology for identifying polymorphisms, i.e. the methods of cloning, PCR and sequencing, were routine in the art at the time the invention was made is not sufficient to establish that it is routine in the art to identify specific polymorphisms associated with BP. As discussed in the declaration, the majority of polymorphisms identified in the stated experiments were not in fact associated with BP. Thus, even after one has performed the research to identify new

polymorphisms in the 500 kb interval, there is no predictable means for identifying which of these polymorphisms will be associated with BP and the polymorphisms associated with BP can only be identified through additional experimentation. The declaration provides the selected results of a study, but does not clearly establish that merely routine experimentation is required to identify a representative number of specific polymorphisms in this 500 kb interval which are associated with BP.

With respect to the PCT publication WO 99/47535 previously cited by Applicants, it is argued that this reference establishes that the instant specification is enabling. Applicants state that "the claimed methods do not require characterization of a gene nor was characterization of a gene a prerequisite for identification of the polymorphism associated with BP discussed in WO 99/47535." This argument is not convincing because the WO 99/47535 clearly establishes that extensive experimentation was in fact required to identify the HKNG1 gene and the polymorphism in this gene that is associated with BP. The present specification does not provide the specific guidance to lead one of skill in the art to the HKNG1 gene, or to the specific mutation within this gene that was found to be associated with BP. As discussed previously, WO 99/47535 (see pages 4-5) highlights the unpredictability in the art in identifying a specific loci associated with BP disorder (referred to therein as "BAD"), stating that:

"Mapping genes for common diseases believed to be caused by multiple genes, such as BAD, may be complicated by the typically imprecise definition of phenotypes, by etiological heterogeneity, and by uncertainty about the mode of transmission of the disease trait. With neuropsychiatric disorders there is even greater ambiguity in distinguishing individuals who carry an affected genotype from those that are genetically unaffected...Also, with complex traits such as neuropsychiatric disorders, it is difficult to genetically map the trait-causing genes because: (1) neuropsychiatric disorder phenotypes do not exhibit classic Mendelian recessive or dominant inheritance patterns

attributable to a single locus, (2) there may be incomplete penetrance, i.e., individuals who do not inherit a predisposing allele may not manifest disease; (3) a phenocopy phenomenon may occur, i.e., individuals who do not inherit a predisposing allele may nevertheless develop disease due to environmental or random causes; (4) genetic heterogeneity may exist, in which case mutations in any one of several genes may result in identical phenotypes."

Applicant's arguments that the characterization of a gene was not a prerequisite for identifying a polymorphism in the WO 99/47535 document have been fully considered. However, the teachings in this WO document make clear that the polymorphism was only identified after the gene associated with BP was first isolated. Furthermore, it is again pointed out that the methodology disclosed in the specification for identifying polymorphisms does in fact require identifying a gene associated with BP (see page 31 of the specification). Additionally, the claims as written are inclusive of methods which detect specific alterations, including point mutations, deletions and additions, in a gene associated with BP. Further, claims 10 and 11 are drawn to methods in which a BP polymorphism is detected in the general population and the claims do not require an analysis of blood relatives. However, the region between SAVA5 and ga203 is expected to contain numerous polymorphisms and mutations that are not associated with BP. Thereby, the detection of these variants in the general population would not be predictive of susceptibility to BP. Only specific polymorphisms and mutations within the defined region will be found to be correlated with BP. The specification does not provide sufficient guidance as to how to apply the claimed method of diagnosis to the general population by detecting the presence of any polymorphism between SAVA5 and ga203.

Lastly, it is again pointed out that the claims are directed to a research project. The claims require performing method steps in which a polymorphism is discovered by either typing blood relatives of an individual for the presence of a polymorphism and then determining whether any of these polymorphisms are associated with a phenotypic diagnosis of BP or by analyzing DNA from an individual for the presence of a polymorphism and then determining the frequency of the polymorphism on disease chromosomes and non-disease chromosomes, wherein over representation of a polymorphism indicates that the polymorphism is associated with a form of bipolar mood disorder. The specification has not provided sufficient guidance to enable one of skill in the art to practice such methods of identifying novel polymorphisms without undue experimentation.

**3. THE FOLLOWING ARE NEW GROUNDS OF REJECTION NECESSITATED BY
APPLICANTS AMENDMENTS TO THE CLAIMS:**

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-7, 25 and 26 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1-7, 25 and 26 are indefinite over the recitation of "correlating the presence or absence of the DNA polymorphism with a phenotypic diagnosis of bipolar mood disorder for said individual **or for said family member.**" The claims are drawn to methods for detecting an increased susceptibility to bipolar in an individual and thereby

it is unclear as to how the step of correlating the polymorphism with the diagnosis of BP in a family member relates to the remainder of the claim. It is unclear as to how one would interpret the results of the pedigree analysis and it is unclear as to whether the method is one which detects increased susceptibility to BP in an individual or one in which the presence of a polymorphism is correlated with a phenotypic diagnosis of BP in a family member.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carla Myers whose telephone number is (703) 308-2199. The examiner can normally be reached on Monday-Thursday from 6:30 AM-5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (703)-308-1119. Papers related to this

Application/Control Number: 08/976,560
Art Unit: 1634

Page 16

application may be faxed to Group 1634 via the PTO Fax Center using the fax number (703)-872-9306.

Any inquiry of a general nature or relating to the status of this application should be directed to the receptionist whose telephone number is (703) 308-0196.

Carla Myers

August 5, 2003

Carla Myers
CARLA J. MYERS
PRIMARY EXAMINER